LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Method Rapidly Monitors Sickle Cell Disease

By LabMedica International staff writers
Posted on 26 Jun 2019
Print article
Image: A peripheral blood film from a patient with sickle cell disease (Photo courtesy of Venngage).
Image: A peripheral blood film from a patient with sickle cell disease (Photo courtesy of Venngage).
Sickle cell disease (SCD) is a hereditary disorder that affects red blood cells, distorting their natural disc shape into a crescent moon or "sickle" shape. Normal red blood cells move freely through small vessels throughout the body to deliver oxygen. With sickle cell disease, the misshapen red blood cells become hard and sticky, making it difficult for them to move through blood vessels.

Sickle cell disease affects millions of people of many nationalities throughout the world, including both children and adults. A major challenge in managing the disease is the tremendous pain that patients endure from chronic and acute pain episodes called pain crisis. Unfortunately, these pain episodes are unpredictable and patients never know when or where these episodes will take place.

Bioengineers at the Florida Atlantic University (Boca Raton, FL, USA) and their hematologist colleague have developed a rapid and reliable new method to continuously monitor sickle cell disease using a microfluidics-based electrical impedance sensor. This novel technology can characterize the dynamic cell sickling and unsickling processes in sickle blood without the use of microscopic imaging or biochemical markers. The team collected five blood samples from individuals with SCD. A normal blood sample was obtained from a local blood bank and used as a control in the study. All samples were stored at 4 °C and tested within two weeks of collection.

Normalized impedance of all the five samples during the first hypoxia session were compared, allowing the scientists to identify intersample variations. The difference in sickling behavior was substantial. The team also established the correlations between the in vitro measurements and the patients' hematological parameters, such as the levels of sickle hemoglobin (HbS) and fetal hemoglobin (HbF). These findings show a potential clinical relevance because it serves as a proof-of-concept of electrical impedance as a label-free, biophysical marker of cell sickling events as well as a sensitive tool for probing the dynamic cellular and subcellular processes beyond the optical microscopy. The developed electrical impedance sensor may potentially be used for assessing vaso-occlusion risk, disease severity, and therapeutic treatment in sickle cell disease.

Sarah E. Du, PhD, an assistant professor and senior author of the study said, “The combination of electrical impedance measurement and on-chip hypoxia control provides a promising method for rapid assessment of the dynamic processes of cell sickling and unsickling in patients with sickle cell disease. In addition, electrical impedance measurement is naturally quantitative, real-time, and offers a convenience in direct or indirect contact with the samples of interest, allowing integrations to microfluidics platform and optical microscopy.” The study was published on May 14, 2019, in the journal ACS Sensors.

Related Links:
Florida Atlantic University

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.